Fig. 1.
Overall survival is increased with the addition of IFN-α-2b. a Progression-free survival curves comparing those patients not receiving IFN-α-2b (Cohort 0) to those receiving any dose of IFN-α-2b (Cohorts 1–4). b Overall survival curves comparing those patients not receiving IFN-α-2b (Cohort 0) to those receiving any dose of IFN-α-2b (Cohorts 1–4). c Progression-free survival curves and d overall survival curves comparing all five study arms: Cohort 0, no IFN-α-2b; Cohort 1, IFN-α-2b (1 × 106 U); Cohort 2, IFN-α-2b (3 × 106 U); Cohort 3, IFN-α-2b (6 × 106 U); and Cohort 4, IFN-α-2b (9 × 106 U)